title: Placental expression of proteases and their inhibitors in patients with HELLP syndrome.
abstract: In preeclampsia and hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome, impaired trophoblast invasion and excessive fibrin deposition in the placental intervillous space is associated with fetal compromise. However, little information is available whether modulation of placental protease expression--potentially causing impaired trophoblast invasion--is associated with the HELLP syndrome. Total RNA and protein were extracted from placental tissue from 11 females with HELLP syndrome and 8 controls matched for gestational age. mRNA expression of matrix metalloprotease (MMP) -2 and -9, tissue inhibitors of metalloprotease (TIMP) -1, -2, and -3, and urokinase-type plasminogen activator receptor (uPAR) was determined by Northern blotting. Protein expression of MMP-2 and -9, and TIMP-1 and -2 was detected by Western blotting and that of uPA, uPAR, and plasminogen activator inhibitor (PAI) -1 by ELISA. In patients with HELLP syndrome, mRNA expression of MMP-2 and TIMP-2 was decreased, whereas TIMP-1 and -3 levels were unchanged. MMP-9 and uPAR mRNA was undetectable in both groups. Protein expression of all investigated proteolytic factors remained unchanged. Our findings at the mRNA level suggest a decrease in matrix remodeling in placentae from patients with HELLP syndrome compared with control pregnancies, although this is not supported at the protein level.
authors: Abteilung Perinatalmedizin, Frauenklinik und Poliklinik der Technischen Universität München, Klinikum rechts der Isar, D-81675 München, Germany. spvs@lrz.tum.de
authors: Stephanie Pildner
authors: SP
authors: von Steinburg
authors: Achim
authors: A
authors: Krüger
authors: Thorsten
authors: T
authors: Fischer
authors: Karl-Theodor
authors: KT
authors: Mario Schneider
authors: Manfred
authors: M
authors: Schmitt
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D017359:HELLP Syndrome / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D020782:Matrix Metalloproteinases / Q000235:genetics* / Q000378:metabolism*; D010920:Placenta / Q000378:metabolism* / Q000473:pathology; D011247:Pregnancy; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator / Q000235:genetics / Q000378:metabolism; D019714:Tissue Inhibitor of Metalloproteinases / Q000235:genetics* / Q000378:metabolism*
chemical_list: D012333:RNA, Messenger; D055293:Receptors, Urokinase Plasminogen Activator; D019714:Tissue Inhibitor of Metalloproteinases; D020782:Matrix Metalloproteinases